image credit: Pixabay

Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing

February 27, 2020

Via: BioSpace

RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal proteins or an overproduction of proteins, which can be treated by turning off or silencing the gene. One of the companies working on the cutting edge of this field is Pasadena, California-based Arrowhead Pharmaceuticals, which is expecting 2020 to be a real inflection point.

Christopher Anzalone, the company’s chief executive officer, took time to speak with BioSpace about the company’s large pipeline and why they’re so excited about 2020.

Read More on BioSpace